Across TCGA pan-cancer cohorts, PRR3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRR3 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher PRR3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRR3 expression acts as an unfavorable survival marker.

CHOL and SKCM are the cancer types where PRR3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	All	0.758	0.873	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRR3 tumor-vs-normal RNA expression · all PRR3 data types